Loading stock data…
CYCN
$3.00-0.01 (-0.33%)
After Hours$3.00+0.00 (+0.00%)· Last close Jun 9
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cyclerion Therapeutics, Inc. in the Healthcare sector is trading at $3.00. Wall Street consensus targets $8.00 (1 analysts), implying a +166.7% move over the next 12 months. The stock is currently 65% below its 52-week high of $8.48, remaining 40.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +166.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.00
Potential Downside
0%
Whystock Fair Value$3.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.69%
Volume
Today's trading volume
22,999
Recent News
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline
Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Cyclerion Therapeutics Inc. (NASDAQ:CYCN) is one of the unstoppable stocks that could double your money. On April 1, Cyclerion and Korsana Biosciences entered into a definitive merger agreement to form a combined entity operating under the name Korsana Biosciences, […]
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?
Cyclerion stock soared on a merger agreement with privately held Korsana Biosciences. But there are ample reasons for disciplined investors to avoid chasing the rally in CYCN shares.
Top Midday Gainers
Cyclerion Therapeutics (CYCN) and Korsana Biosciences, a privately-held biotechnology firm, said Wed
BC-Most Active Stocks
HIVE Digital Technologies Ltd. 18,936,738 3.09
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal
Akebia Therapeutics (AKBA) said Monday that it has built a rare kidney disease pipeline around a com